BLFSBioLife Solutions, Inc.
Is the price fair?
A demanding price: priced for a lot of growth and rich vs its sector.
Priced for ~34% a year FCF growth. The price already bakes in strong, sustained growth.
Sector median 22.6× across 130 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.
All from derived, as of Jun 30, 2026.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What BLFS's price assumes
BioLife Solutions, Inc. trades at 33.0× earnings against 39.6× for the median Medical Instruments & Supplies name, cheaper than its own group.
Trailing P/E · Medical Instruments & Supplies median 39.6 · cheaper than the typical name in its group
- Price / sales
- 13.1
Price / sales · today's price, trailing year to Jun 30, 2026
- Free cash flow yield
- 0.64%
Free cash flow yield · Medical Instruments & Supplies median 3.4%
- Growth the price implies
- +34%
Growth the price implies · What free cash flow would have to do every year for a decade to justify today's price, discounted at 9.0%.
Details›
- Price / booktoday's price, trailing year to Jun 30, 2026
- 3.20
- EV / EBIToperating margin 2.9%: the multiple describes the denominator
- not meaningful
- EV / salestoday's price, trailing year to Jun 30, 2026
- 12.3
- Healthcare median P/E509 names
- 26.2
- Medical Instruments & Supplies median P/E33 names
- 39.6
- Free cash flow, trailing twelve months
- $8.6M
- Market capitalisation
- $1.34B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Medical Instruments & Supplies
Ranks #18 of 21 by RyuScore